Pharm
Serotonin Syndrome
search
Serotonin Syndrome
, Serotonergic Medication
See Also
Serotonin
Neurotransmitter Physiology
Neuroleptic Malignant Syndrome
Malignant Hyperthermia
Background
History
Libby Zion was a young patient who died of Serotonin Syndrome in 1984 and set historic precedent
Provider education regarding Serotonin Syndrome
Principal case that limited intern and resident shift hours
http://en.wikipedia.org/wiki/Libby_Zion_law
Epidemiology
Complicates 14-16% of
SSRI Overdose
s
Isbister (2004) J Toxicol Clin Toxicol 42(3): 277-85 [PubMed]
Etiology
Excessive
Serotonin
levels at the 5HT-2A receptor sites
Associated with combinations of
Serotoninergic
drugs (e.g.
SSRI
, TCA,
MAOI
)
Exacerbated by drugs that increase
Serotonin
levels (see risk factors below)
Risk Factors
Gene
ral
Medications with serotonergic effects (see below)
Combined use of multiple serotonergic drugs
Inadequate washout period between transitioning to a new serotonergic drug
Higher
Incidence
with
Monoamine Oxidase Inhibitor
s,
St. John's Wort
and
Linezolid
Cytochrome P450
Drug Interaction
s or specific patient
Phenotype
s
Examples:
Clarithromycin
Increases susceptibility to Serotonin Syndrome
Medical conditions that decrease the available monoamine oxidase
Hypertension
Atherosclerosis
Hyperlipidemia
Risk Factors
Serotonergic Medications
Psychiatric medications
Selective Serotonin Reuptake Inhibitor
s -
SSRI
(e.g.
Paroxetine
/
Paxil
or
Fluoxetine
/
Prozac
)
Serotonin
-
Norepinephrine
Reuptake Inhibitors -
SNRI
(e.g.
Venlafaxine
-
Effexor
)
MAO Inhibitor
s (e.g.
Phenelzine
,
Selegiline
or
Nardil
)
High risk for Serotonin Syndrome when combined with other serotinergic agents
Tricyclic Antidepressant
s (e.g.
Amitriptyline
,
Clomipramine
,
Imipramine
)
Lithium
Buspar
Trazodone
Lower risk of Serotonin Syndrome (non-
Serotonin
2A stimulation)
Some
Antipsychotic Medication
s (e.g.
Olanzapine
or
Zyprexa
)
Stimulant Medication
s
Methylphenidate
(
Ritalin
)
Sibutramine
(
Meridia
)
Antiemetic
s
Metoclopramide
(
Reglan
)
Ondansetron
(
Zofran
)
Lower risk of Serotonin Syndrome (non-
Serotonin
2A stimulation)
Droperidol
(
Inapsine
)
Migraine
and
Seizure
Medications
Triptan
s (e.g.
Sumatriptan
Imitrex
)
Lower risk of Serotonin Syndrome (non-
Serotonin
2A stimulation)
Ergot Alkaloids
Valproic Acid
(
Depakote
,
Depakene
)
Carbamazepine
(
Tegretol
)
Synthetic
Opioid Analgesic
s
Tramadol
(
Ultram
)
Higher risk for Serotonin Syndrome
Meperidine
(
Demerol
)
Fentanyl
(
Duragesic
)
Methadone
Dextromethorphan
Rare case reports with
Buprenorphine
(
Suboxone
),
Hydromorphone
,
Oxycodone
or
Hydrocodone
Muscle
Relaxants
Cyclobenzaprine
(
Flexeril
)
Metaxalone
(
Skelaxin
)
Miscellaneous medications
Chlorpheniramine
Linezolid
(
Zyvox
) -
MAO Inhibitor
effect
Reserpine
Ritonavir
(
Norvir
)
Locaserin (weight loss agent)
Herbals
and supplements
St. John's Wort
Ginkgo Biloba
Ginseng
L-
Tryptophan
5-Hydroxytryptophan (dietary supplement) -
Serotonin
precursor
Yohimbine
Recreational drugs
Cocaine
3,4-methylenedioxmethamphetamine (Ecstacy)
Methamphetamine
Signs
Mental Status Changes
Confusion or
Disorientation
(51%)
Agitation
or irritability (34%)
Somnolence
, coma or unresponsiveness (29%)
Autonomic changes
Fever
or hyperthermia (45%)
Muscle
hyperactivity and decreased heat dissipation
Diaphoresis (45%)
Sinus Tachycardia
(36%)
Hypertension
(35%)
Mydriasis
(28%) or unreactive pupils (20%)
Tachypnea
(26%)
Nausea
(23%) or
Vomiting
Neuromuscular changes
Myoclonic Jerk
s (58%)
Hyperreflexia (52%)
Muscle
rigidity (51%)
Restlessness or hyperactivity (48%)
Tremor
(43%)
Ataxia
or
Incoordination
(40%)
Clonus
(23%)
Spontaneous
Clonus
with a history of
Serotoninergic
agent use is pathognomonic for Serotonin Syndrome
Dunkley (2003) QJM 96 (9): 635-642 [PubMed]
Exclude other possible causes
Infectious, metabolic,
Substance Abuse
or withdrawal
No recent
Neuroleptic
changes
Precautions
Subtle Serotonin Syndrome presentations are far more common than severe Serotonin Syndrome (e.g.
Delirium
, hyperthermia)
Remain alert for more subtle findings (e.g.
Agitation
, diaphoresis,
Tremor
)
Focus on times of dose increase and times of new medications (especially in combination)
Diagnosis
Hunter
Serotonin
Criteria
Major Criteria
Ingestion of serotinergic agent
Other Criteria (at least one present)
Tremor
AND Hyperreflexia
Spontaneous
Clonus
Ocular
Clonus
or Inducible
Clonus
AND one of the following
Hypertonia AND
Body Temperature
> 100.4 F (38 C) OR
Agitation
Diaphoresis
Efficacy
Test Sensitivity
: 84%
Test Specificity
: 97%
References
Dunkley (2003) QJM 96(9):635-42 +PMID: 12925718 [PubMed]
Differential Diagnosis
Meningitis
or
Encephalitis
Anticholinergic Syndrome
Malignant Hyperthermia
Seizure Disorder
Neuroleptic Malignant Syndrome
Occurs with
Dopamine
blocking agents
Classic triad of fever,
Muscle
rigidity and
Altered Mental Status
Management
Discontinue
Serotoninergic
medications
Provide supportive care
Treat
Muscle
rigidity,
Tremor
and hyperthermia
First line
Benzodiazepine
s decrease
Agitation
and adrenergic stress
Refractory Hyperthermia (severe, critically ill patients)
Active Cooling of Patient
Endotracheal Intubation
Sedation and
Paralytic Agent
s (non-depolarizing
Neuromuscular Blocker
s, e.g.
Rocuronium
)
Consider serotonin
Antagonist
s
Cyproheptadine
(
Periactin
)
Initial protocol
Bolus: 12 mg oral bolus dose for 1 dose (may be crushed and placed down NG or OG)
Continued symptoms: 2 mg every 2 hours until symptoms controlled
Expect patient sedation with
Cyproheptadine
dosing
Maintenance protocol (once stabilized)
Dose: 8 mg every 6 hours or 4 mg every 2-4 hours
Maximum: 0.5 mg/kg/day
Other medications that have been used for Serotonin Syndrome symptom control
Propranolol
Precautions
Avoid
Antipsychotic
s (e.g.
Haloperidol
) as has serotonergic effects and may exacerbate condition
Avoid antipyretics (ineffective)
Hyperthermia of Serotonin Syndrome is due to increased
Muscle
activity (not the
Hypothalamus
)
Course
Many cases likely go undiagnosed and resolve spontaneously when patients stop the medications themselves
Resolution after stopping
Serotoninergic
medication
Within 24 hours in 70% of cases
Within 96 hours in almost all cases
High acuity care
Intensive Care
admission in up to 40% of cases
Mechanical Ventilation
in up to 25% of cases
Rarely fatal: 11 deaths in literature
References
Herbert and Jhun in Herbert (2015) EM:Rap 15(4):14
Nordt and Swadron in Majoewsky (2012) EM:Rap 12(2): 3
Otter and Tomaszewski (2018) Crit Dec Emerg Med 32(11): 28
(2022) Presc Lett 29(9): 51-2
Ables (2010) Am Fam Physician 81(9): 1139-42 [PubMed]
Bodner (1995) Neurology 45:219-23 [PubMed]
Brown (1996) Ann Pharmacother 30:529-33 [PubMed]
Corkeron (1995) Med J Aust 163:481-2 [PubMed]
Erner (2003) Pain Med 4(1): 63-74 [PubMed]
Iqbal (2012) Ann Clin Psychiatry 24(4): 310-8 [PubMed]
Kovich (2015) Am Fam Physician 92(2): 94-100 [PubMed]
Mills (1995) Am Fam Physician 52(5):1475-82 [PubMed]
Type your search phrase here